News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Portola Pharmaceuticals, Inc. Begins Enrollment In Phase 3 Study Of FDA-Designated Breakthrough Therapy Andexanet Alfa And Factor Xa Inhibitor XARELTO®


5/12/2014 10:01:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that enrollment has begun in a Phase 3 study to evaluate the safety and efficacy of andexanet alfa, the Company's investigational recombinant Factor Xa inhibitor reversal agent, with Bayer HealthCare and Janssen Pharmaceuticals Inc.'s Factor Xa inhibitor XARELTO® (rivaroxaban). Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class agent to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES